| Telomere dysfunction induces metabolic and mitochondrial compromise E Sahin, S Colla, M Liesa, J Moslehi, FL Müller, M Guo, M Cooper, ... Nature 470 (7334), 359-365, 2011 | 1376 | 2011 |
| Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma PR Galle, F Foerster, M Kudo, SL Chan, JM Llovet, S Qin, WR Schelman, ... Liver international 39 (12), 2214-2229, 2019 | 425 | 2019 |
| Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma PR Galle, F Foerster, M Kudo, SL Chan, JM Llovet, S Qin, WR Schelman, ... Liver international 39 (12), 2214-2229, 2019 | 425 | 2019 |
| The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy PR Galle, F Tovoli, F Foerster, MA Wörns, A Cucchetti, L Bolondi Journal of hepatology 67 (1), 173-183, 2017 | 208 | 2017 |
| NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options F Foerster, SJ Gairing, L Müller, PR Galle Journal of hepatology 76 (2), 446-457, 2022 | 129 | 2022 |
| Emerging immunotherapy for HCC: A guide for hepatologists F Foerster, SJ Gairing, SI Ilyas, PR Galle Hepatology 75 (6), 1604-1626, 2022 | 120 | 2022 |
| Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb … M Moehler, J Heo, HC Lee, WY Tak, Y Chao, SW Paik, HJ Yim, KS Byun, ... Oncoimmunology 8 (8), 1615817, 2019 | 107 | 2019 |
| The immune contexture of hepatocellular carcinoma predicts clinical outcome F Foerster, M Hess, A Gerhold-Ay, JU Marquardt, D Becker, PR Galle, ... Scientific reports 8 (1), 5351, 2018 | 97 | 2018 |
| Systemic treatment of HCC in special populations L Rimassa, N Personeni, C Czauderna, F Foerster, P Galle Journal of hepatology 74 (4), 931-943, 2021 | 84 | 2021 |
| Wheat consumption aggravates colitis in mice via amylase trypsin inhibitor–mediated dysbiosis G Pickert, S Wirtz, J Matzner, M Ashfaq-Khan, R Heck, S Rosigkeit, ... Gastroenterology 159 (1), 257-272. e17, 2020 | 48 | 2020 |
| In vivo gene‐silencing in fibrotic liver by siRNA‐loaded cationic nanohydrogel particles L Kaps, L Nuhn, M Aslam, A Brose, F Foerster, S Rosigkeit, P Renz, ... Advanced healthcare materials 4 (18), 2809-2815, 2015 | 48 | 2015 |
| The current landscape of clinical trials for systemic treatment of HCC F Foerster, PR Galle Cancers 13 (8), 1962, 2021 | 47 | 2021 |
| Dextran-based therapeutic nanoparticles for hepatic drug delivery F Foerster, D Bamberger, J Schupp, M Weilbächer, L Kaps, S Strobl, ... Nanomedicine 11 (20), 2663-2677, 2016 | 43 | 2016 |
| Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre F Foerster, M Hoppe-Lotichius, J Vollmar, JU Marquardt, A Weinmann, ... United European Gastroenterology Journal 7 (6), 838-849, 2019 | 36 | 2019 |
| Comparison of the current international guidelines on the management of HCC F Foerster, PR Galle Jhep Reports 1 (2), 114-119, 2019 | 35 | 2019 |
| Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I … M Moehler, A Maderer, A Ehrlich, F Foerster, A Schad, T Nickolay, ... BMC cancer 19, 1-10, 2019 | 29 | 2019 |
| Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells F Foerster, S Boegel, R Heck, G Pickert, N Rüssel, S Rosigkeit, M Bros, ... Oncoimmunology 7 (4), e1409929, 2018 | 27 | 2018 |
| Immunonutritive scoring in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: prognostic nutritional index or controlling nutritional status score? L Müller, F Hahn, A Mähringer-Kunz, F Stoehr, SJ Gairing, F Foerster, ... Frontiers in Oncology 11, 696183, 2021 | 26 | 2021 |
| ZNF365 promotes stability of fragile sites and telomeres Y Zhang, SJ Shin, D Liu, E Ivanova, F Foerster, H Ying, H Zheng, Y Xiao, ... Cancer discovery 3 (7), 798-811, 2013 | 26 | 2013 |
| Immunonutritive scoring for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: evaluation of the CALLY index L Müller, F Hahn, A Mähringer-Kunz, F Stoehr, SJ Gairing, M Michel, ... Cancers 13 (19), 5018, 2021 | 20 | 2021 |
